Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Figure 3 | Arthritis Research & Therapy

Figure 3

From: The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients

Figure 3

Association between clinical improvement (change in Ankylosing Spondylitis Disease Activity Score) and immunogenicity. Change in Ankylosing Spondylitis Disease Activity Score (delta-ASDAS) measured 6 months after switching in spondyloarthritis patients who presented or not anti-drug antibodies (ADA) against the first anti-TNF. Data shown as interquartile ranges (p75, upper edge; p25, lower edge; p50, midline of the box).

Back to article page